{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T14:19:22Z","timestamp":1788963562208,"version":"build-2803163510"},"reference-count":48,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100019827","name":"Atrium Health Foundation","doi-asserted-by":"publisher","award":["5713"],"award-info":[{"award-number":["5713"]}],"id":[{"id":"10.13039\/501100019827","id-type":"DOI","asserted-by":"publisher"}]},{"award":["5713"],"award-info":[{"award-number":["5713"]}],"id":[{"id":"https:\/\/ror.org\/01stnqq35","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Mol. Sci.","IJMS"],"abstract":"<jats:p>Triple-negative breast cancer (TNBC) is a subtype associated with poor prognosis and low survival rates, largely due to limited treatment options. In recent years, histone deacetylase (HDAC) inhibitors have emerged as promising anti-cancer candidates due to their attractive epigenetic properties and distinct mechanisms of action but have shown limited success in solid tumors. Here, we explore ribitoborate along with HDAC inhibitors for potential use as a treatment for TNBC. Experiments were performed on the TNBC cell line MDA-MB-231. The results of the study revealed that ribitoborate and romidepsin showed synergistic responses leading to significant arrest of cell proliferation (80%) (p &lt; 0.01) as well as migration inhibition. These effects were associated with downregulation of c-Myc, survivin, Bcl-2, and cyclin D1, as well as upregulation of p53 and p21 proteins; notably the changes were significantly greater with the combined treatment than with either ribitoborate or romidepsin alone. Romidepsin and ribitoborate combined treatment time-dependently increased cell death of MDA-MB-231 cells with greater efficiency than romidepsin alone. Cell death by apoptosis was supported by the upregulation of H3k9 and H3k27 acetylation with decreasing proliferation. These results suggest the great potential of the drug combination for treatment of TNBC. The underlying molecular mechanisms for synergy could be further explored for potential development of new combined therapy for breast cancer.<\/jats:p>","DOI":"10.3390\/ijms27188033","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T14:02:48Z","timestamp":1788962568000},"page":"8033","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ribitoborate Synergism with Histone Deacetylase Inhibitor Romidepsin as a Potential Treatment for Breast Cancer"],"prefix":"10.3390","volume":"27","author":[{"given":"Ravi","family":"Doddapaneni","sequence":"first","affiliation":[{"name":"McColl-Lockwood Laboratory for Muscular Dystrophy Research, Atrium Health Musculoskeletal Institute, Carolinas Medical Center, Wake Forest University School of Medicine, Charlotte, NC 28203, USA"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"methodology","vocabulary":"credit"},{"role":"software","vocabulary":"credit"},{"role":"validation","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6558-7808","authenticated-orcid":false,"given":"Jason D.","family":"Tucker","sequence":"additional","affiliation":[{"name":"McColl-Lockwood Laboratory for Muscular Dystrophy Research, Atrium Health Musculoskeletal Institute, Carolinas Medical Center, Wake Forest University School of Medicine, Charlotte, NC 28203, USA"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"methodology","vocabulary":"credit"},{"role":"software","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2867-2620","authenticated-orcid":false,"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[{"name":"Fitzsimons Bioscience Park Center, Z Biotech, LLC, Aurora, CO 80045, USA"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"methodology","vocabulary":"credit"},{"role":"validation","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"}]},{"given":"Pei J.","family":"Lu","sequence":"additional","affiliation":[{"name":"McColl-Lockwood Laboratory for Muscular Dystrophy Research, Atrium Health Musculoskeletal Institute, Carolinas Medical Center, Wake Forest University School of Medicine, Charlotte, NC 28203, USA"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"methodology","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"}]},{"given":"Qi L.","family":"Lu","sequence":"additional","affiliation":[{"name":"McColl-Lockwood Laboratory for Muscular Dystrophy Research, Atrium Health Musculoskeletal Institute, Carolinas Medical Center, Wake Forest University School of Medicine, Charlotte, NC 28203, USA"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"project-administration","vocabulary":"credit"},{"role":"funding-acquisition","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"},{"role":"visualization","vocabulary":"credit"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1001\/jama.2024.5479","article-title":"US Breast Cancer Mortality","volume":"331","author":"Jatoi","year":"2024","journal-title":"JAMA"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/s41597-023-02253-5","article-title":"Global trends and forecasts of breast cancer incidence and deaths","volume":"10","author":"Xu","year":"2023","journal-title":"Sci. Data"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Almansour, N.M. (2022). Triple-Negative Breast Cancer: A Brief Review About Epidemiology, Risk Factors, Signaling Pathways, Treatment and Role of Artificial Intelligence. Front. Mol. Biosci., 9.","DOI":"10.3389\/fmolb.2022.836417"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1038\/s41588-025-02322-y","article-title":"Mutational landscape of triple-negative breast cancer in African American women","volume":"57","author":"Yao","year":"2025","journal-title":"Nat. Genet."},{"key":"ref_5","first-page":"721","article-title":"Breast Cancer: An Overview of Current Therapeutic Strategies, Challenge, and Perspectives","volume":"15","author":"Wang","year":"2023","journal-title":"Breast Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jama.2018.19323","article-title":"Breast Cancer Treatment: A Review","volume":"321","author":"Waks","year":"2019","journal-title":"JAMA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S0140-6736(16)31891-8","article-title":"Breast cancer","volume":"389","author":"Harbeck","year":"2017","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/35106079","article-title":"Histone deacetylases and cancer: Causes and therapies","volume":"1","author":"Marks","year":"2001","journal-title":"Nat. Rev. Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1080\/13543776.2023.2219393","article-title":"An updated patent review of histone deacetylase (HDAC) inhibitors in cancer (2020\u2013present)","volume":"33","author":"Liu","year":"2023","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.2174\/0929867311320140005","article-title":"Histone deacetylase inhibitors: An attractive strategy for cancer therapy","volume":"20","author":"Li","year":"2013","journal-title":"Curr. Med. Chem."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.bbrc.2023.09.023","article-title":"HDAC inhibitors: Promising agents for leukemia treatment","volume":"680","author":"Deng","year":"2023","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s13148-010-0006-2","article-title":"Histone deacetylase inhibitors: Clinical implications for hematological malignancies","volume":"1","author":"Tambaro","year":"2010","journal-title":"Clin. Epigenet."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1111\/cas.13062","article-title":"Action mechanisms of histone deacetylase inhibitors in the treatment of hematological malignancies","volume":"107","author":"Imai","year":"2016","journal-title":"Cancer Sci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1002\/cncr.34974","article-title":"Recent histone deacetylase inhibitors in cancer therapy","volume":"129","author":"Parveen","year":"2023","journal-title":"Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1172\/JCI69738","article-title":"New and emerging HDAC inhibitors for cancer treatment","volume":"124","author":"West","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"115938","DOI":"10.1016\/j.ejmech.2023.115938","article-title":"Dual inhibitors of HDAC and other epigenetic regulators: A novel strategy for cancer treatment","volume":"263","author":"Shirbhate","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.3390\/molecules20033898","article-title":"Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents","volume":"20","author":"Mottamal","year":"2015","journal-title":"Molecules"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Hontecillas-Prieto, L., Flores-Campos, R., Silver, A., de Alava, E., Hajji, N., and Garcia-Dominguez, D.J. (2020). Synergistic Enhancement of Cancer Therapy Using HDAC Inhibitors: Opportunity for Clinical Trials. Front. Genet., 11.","DOI":"10.3389\/fgene.2020.578011"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"35","DOI":"10.21873\/anticanres.11286","article-title":"Histone Deacetylase Inhibitors: An Attractive Therapeutic Strategy Against Breast Cancer","volume":"37","author":"Damaskos","year":"2017","journal-title":"Anticancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Suraweera, A., O\u2019Byrne, K.J., and Richard, D.J. (2018). Combination Therapy with Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi. Front. Oncol., 8.","DOI":"10.3389\/fonc.2018.00092"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4935","DOI":"10.1038\/s41598-020-61747-z","article-title":"Ribitol enhances matriglycan of alpha-dystroglycan in breast cancer cells without affecting cell growth","volume":"10","author":"Lu","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Tucker, J.D., Doddapaneni, R., Lu, P.J., and Lu, Q.L. (2022). Ribitol alters multiple metabolic pathways of central carbon metabolism with enhanced glycolysis: A metabolomics and transcriptomics profiling of breast cancer. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0278711"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Doddapaneni, R., Tucker, J.D., Lu, P.J., and Lu, Q.L. (2023). Metabolic Reprogramming by Ribitol Expands the Therapeutic Window of BETi JQ1 against Breast Cancer. Cancers, 15.","DOI":"10.3390\/cancers15174356"},{"key":"ref_24","first-page":"135","article-title":"Velcade (Bortezomib) Receives 2 New FDA Indications: For Retreatment of Patients with Multiple Myeloma and for First-Line Treatment of Patients with Mantle-Cell Lymphoma","volume":"8","author":"Raedler","year":"2015","journal-title":"Am. Health Drug Benefits"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Lica, J.J., Pradhan, B., Safi, K., Jakobkiewicz-Banecka, J., and Hellmann, A. (2024). Promising Therapeutic Strategies for Hematologic Malignancies: Innovations and Potential. Molecules, 29.","DOI":"10.3390\/molecules29174280"},{"key":"ref_26","first-page":"101074","article-title":"Hematologic malignancies and an overview of emerging therapies for hematologic malignancies: A systematic review","volume":"46","author":"Ghaffari","year":"2026","journal-title":"Cancer Treat. Res. Commun."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Hu, Z., and Bousbaa, H. (2025). Recent Advances in Anticancer Strategies. Cancers, 17.","DOI":"10.3390\/books978-3-7258-4218-6"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"10023","DOI":"10.1007\/s11033-022-07571-2","article-title":"Breast cancer in the era of precision medicine","volume":"49","author":"Sarhangi","year":"2022","journal-title":"Mol. Biol. Rep."},{"key":"ref_29","first-page":"846","article-title":"Histone deacetylase inhibitors as a new anticancer option: How far can we go with expectations? delivery systems","volume":"23","author":"Garmpi","year":"2018","journal-title":"J. BUON"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1517\/14656566.2010.534779","article-title":"Emerging role of the histone deacetylase inhibitor romidepsin in hematologic malignancies","volume":"11","author":"Jain","year":"2010","journal-title":"Expert. Opin. Pharmacother."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood-2012-08-450916","article-title":"Dosage-dependent tumor suppression by histone deacetylases 1 and 2 through regulation of c-Myc collaborating genes and p53 function","volume":"121","author":"Heideman","year":"2013","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13045-024-01551-8","article-title":"Advances in targeting histone deacetylase for treatment of solid tumors","volume":"17","author":"Shi","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/CAD.0000000000000040","article-title":"Histone deacetylase inhibitors: An overview of the clinical studies in solid tumors","volume":"25","author":"Slingerland","year":"2014","journal-title":"Anticancer Drugs"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Eckschlager, T., Plch, J., Stiborova, M., and Hrabeta, J. (2017). Histone Deacetylase Inhibitors as Anticancer Drugs. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18071414"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Wang, T.K., Xu, S., Fan, Y., Wu, J., Wang, Z., Chen, Y., and Zhang, Y. (2023). The Synergistic Effect of Proanthocyanidin and HDAC Inhibitor Inhibit Breast Cancer Cell Growth and Promote Apoptosis. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241310476"},{"key":"ref_36","first-page":"219","article-title":"The class I HDAC inhibitor Romidepsin targets inflammatory breast cancer tumor emboli and synergizes with paclitaxel to inhibit metastasis","volume":"10","author":"Robertson","year":"2013","journal-title":"J. Exp. Ther. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1016\/j.apsb.2023.02.007","article-title":"Targeting histone deacetylases for cancer therapy: Trends and challenges","volume":"13","author":"Liang","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Doddapaneni, R., Tucker, J.D., Lu, P.J., and Lu, Q.L. (2025). Synergistic Effect of Ribitol and Shikonin Promotes Apoptosis in Breast Cancer Cells. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26062661"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.molonc.2012.09.003","article-title":"HDAC inhibitor-based therapies: Can we interpret the code?","volume":"6","author":"New","year":"2012","journal-title":"Mol. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/ja.2011.35","article-title":"Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): A natural product recently approved for cutaneous T-cell lymphoma","volume":"64","author":"VanderMolen","year":"2011","journal-title":"J. Antibiot."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"28004","DOI":"10.1038\/srep28004","article-title":"Synergistic effects of combined treatment with histone deacetylase inhibitor suberoylanilide hydroxamic acid and TRAIL on human breast cancer cells","volume":"6","author":"Zhou","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/s41416-020-0877-8","article-title":"Compensatory combination of romidepsin with gemcitabine and cisplatin to effectively and safely control urothelial carcinoma","volume":"123","author":"Pattarawat","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.4161\/cc.9.9.11543","article-title":"Romidepsin (FK228\/depsipeptide) controls growth and induces apoptosis in neuroblastoma tumor cells","volume":"9","author":"Panicker","year":"2010","journal-title":"Cell Cycle"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.biopha.2014.01.002","article-title":"Romidepsin induces cell cycle arrest, apoptosis, histone hyperacetylation and reduces matrix metalloproteinases 2 and 9 expression in bortezomib sensitized non-small cell lung cancer cells","volume":"68","author":"Karthik","year":"2014","journal-title":"Biomed. Pharmacother."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"114774","DOI":"10.1016\/j.biopha.2023.114774","article-title":"Molecular mechanistic pathways underlying the anticancer therapeutic efficiency of romidepsin","volume":"164","author":"Lee","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"ref_46","unstructured":"BridgeBio (2025). BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I\/R9, BridgeBio Pharma, Inc.. Available online: https:\/\/investor.bridgebio.com\/news\/news-details\/2026\/BBP-418-Demonstrates-Consistent-Efficacy-and-Favorable-Safety-Profile-in-Phase-3-FORTIFY-Interim-Analysis-in-LGMD2IR9\/default.aspx."},{"key":"ref_47","unstructured":"ClinicalTrials.gov (2026, July 14). Study to Evaluate the Efficacy and Safety of BBP-418 (Ribitol) in Patients with Limb Girdle Muscular Dystrophy 2I (LGMD2I) (Fortify), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05775848."},{"key":"ref_48","first-page":"43","article-title":"Current Methods for Quantifying Drug Synergism","volume":"1","author":"Ma","year":"2019","journal-title":"Proteome Bioinform."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/18\/8033\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T14:04:47Z","timestamp":1788962687000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/18\/8033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":48,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["ijms27188033"],"URL":"https:\/\/doi.org\/10.3390\/ijms27188033","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]}}}